L ipoprotein(a) [Lp(a)] is a circulating lipoprotein composed of an apolipoprotein B100 (ApoB) molecule covalently bound to a liver-derived glycoprotein, apolipoprotein(a) [Apo(a)]. 1 Apo(a) is encoded by the LPA gene on chromosome 6 and shares structural homology with plasminogen. 2 Lp(a) is postulated to play a role in tissue healing and innate immunity, but its precise physiological role remains undefined. 3 It is increasingly recognized as having both proatherosclerotic and prothrombotic Background-Lipoprotein(a) [Lp(a)] is an emerging risk factor for cardiovascular disease. Currently, there are few available therapies to lower Lp(a). We sought to evaluate the impact of AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), on Lp(a).
effects. 3 Specifically, Lp(a) promotes smooth muscle cell proliferation, endothelial cell adhesion molecule expression, foam cell generation, and endothelial dysfunction. Moreover, given its structural similarity to plasminogen, it acts as a competitive inhibitor for plasminogen and has antifibrinolytic effects.
Clinical Perspective on p 969
In epidemiological and genetic analyses, Lp(a) has emerged as an important risk factor for the development of cardiovascular disease (CVD). [4] [5] [6] On the basis of these data, the 2010 European Society of Atherosclerosis issued a consensus statement recommending assessment of Lp(a) in individuals with premature CVD, familial hypercholesterolemia, a family history of premature CVD or elevated Lp(a), or recurrent CVD despite statin therapy. 7 The 2011 European Society of Cardiology/European Society of Atherosclerosis guidelines are also consistent with this approach, recommending screening for elevated Lp(a) in people at high risk for CVD or with a strong family history of premature atherothrombotic disease. 8 There are limited therapeutic options for lowering Lp(a) levels. Beyond niacin, which at daily doses of 2 to 4 g reduces Lp(a) by ≈30%, other therapies such aspirin, fibrates, and thyroid hormone supplementation offer modest reductions in Lp(a). [9] [10] [11] [12] [13] The impact of statins on Lp(a) remains a point of controversy, but most analyses suggest a neutral effect or an increase in Lp(a) levels. 14, 15 AMG145 is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PCSK9), a protein synthesized and secreted by the hepatocyte, that binds to the low-density lipoprotein (LDL) receptor, targeting it for lysosomal degradation. In the LDL-C Assessment with PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial, AMG145 compared with placebo led to significant, dose-dependent reductions in LDL cholesterol (LDL-C) of up to 66% at week 12 in patients with hypercholesterolemia receiving statin therapy with or without ezetimibe. 16 We sought to evaluate the impact of PCSK9 inhibition with AMG145 on Lp(a) in this patient population.
Methods

Study Population and Treatment
The design, rationale, and primary findings of the LAPLACE-TIMI 57 trial were published previously. 16, 17 In brief, the study was a phase 2, double-blind, placebo-controlled, dose-ranging study of AMG145 versus placebo in 631 subjects with hypercholesterolemia and LDL-C ≥85 mg/dL on a stable dose of statin therapy with or without ezetimibe. At baseline, 30% of subjects were receiving intensive statin therapy, defined as daily simvastatin 80 mg, atorvastatin ≥40 mg, rosuvastatin ≥20 mg, or any statin in combination with ezetimibe. Subjects were randomized equally across 8 treatment arms: AMG145 70 mg, 105 mg, 140 mg, or matching placebo every 2 weeks or AMG145 280 mg, 350 mg, 420 mg, or matching placebo every 4 weeks. Blood samples for Lp(a) assessment were collected at baseline (on the day of randomization but before the first dose of study drug) and at week 12 as part of this prespecified analysis. Lp(a) was measured with the use of a Polymedco immunoturbidimetric assay that is independent of Lp(a) particle size (Cortlandt Manor, NY; intra-assay coefficient of variation ≤4.1%; interassay coefficient of variation ≤8.5%; limit of detection 5 nmol/L) at a Medpace Reference Laboratory (see the online-only Data Supplement for further details). The baseline and week-12 LDL-C was measured by preparative ultracentrifugation at the Lipid Core Laboratory (Cincinnati, OH).
Statistical Analysis
Normality of the distribution of baseline Lp(a) and Lp(a) at week 12 and the absolute and percent changes in Lp(a) from baseline to week 12 were evaluated with the Shapiro-Wilk test of normality. Because of nonnormality of Lp(a) at baseline and week 12 even after log-transformation, median (interquartile range [IQR]) values are reported, and nonparametric tests were used for statistical inference. The absolute and percent changes in Lp(a) from baseline to week 12 were approximately normally distributed. The correlation between baseline, absolute change, and percent change in Lp(a) and similar assessments of LDL-C and other lipid parameters were evaluated with the Spearman correlation coefficient. Baseline clinical factors, demographic characteristics, and lipid parameters were assessed as univariate predictors of baseline Lp(a) greater than or equal to the median. Multivariable logistic regression models were developed with the use of a backward selection method applied to all factors that achieved P<0.25 on univariate testing to identify independent factors associated with baseline Lp(a) greater than or equal to the median. The least squares mean percent change in Lp(a) from baseline to week 12 for each treatment arm compared with placebo was calculated with the use of ANCOVA models with covariates for treatment group, LDL-C at study entry (<130 versus ≥130 mg/dL), and baseline use of ezetimibe (yes versus no). Formal interaction testing was performed to assess for heterogeneity across binary subgroups for subjects receiving AMG145 140 mg every 2 weeks or 420 mg every 4 weeks compared with placebo with the use of ANCOVA models. A linear trend interaction test was performed when assessing for heterogeneity across quartile of baseline Lp(a) (excluding subjects with nonquantifiable level) and baseline LDL-C. The absolute difference in Lp(a) from baseline to week 12 for each AMG145 dose versus placebo was compared with the Wilcoxon rank sum test. For all analyses of the change in Lp(a) from baseline to week 12, only subjects who had Lp(a) assessed at both time points were included. For all analyses, P<0.05 was considered significant. All analyses were performed by the TIMI Study Group with the use of an independent copy of the complete clinical trial database. The authors wrote all drafts of the article and take responsibility for its content.
Results
Of the 631 randomized subjects in the LAPLACE-TIMI 57 trial, 626 subjects (99%) had Lp(a) assessed at baseline, and 612 (97%) had Lp(a) assessed at both baseline and week 12. The distribution of Lp(a) at baseline is shown in Figure I in the onlineonly Data Supplement. The distribution was positively skewed with a long right tail: the mean was 95 nmol/L, and the median (IQR) was 43 (13-161) nmol/L. The distribution of baseline Lp(a) stratified by race demonstrated significant heterogeneity, with higher levels among blacks than among whites (P<0.0001; Figure IIA and IIB in the online-only Data Supplement). There was no correlation between baseline Lp(a) and baseline LDL-C (ρ=0.005, P=0.89) or other related lipid parameters ( Table I in the online-only Data Supplement). There were weak correlations, some statistically significant, between baseline Lp(a) levels and baseline levels of high-density lipoprotein cholesterol (ρ=0.09, P=0.02), apolipoprotein A1 (ρ=0.08, P=0.06), triglycerides (ρ=−0.13, P=0.001), and PCSK9 (ρ=0.09, P=0.03) ( Table I in 
the online-only Data Supplement).
Baseline characteristics for the cohort overall and for subjects with baseline Lp(a) less than versus greater than or equal to the median are shown in Table 1 . Overall, the mean age was 61 years, 51% were female, 89% were white, 29% had a prior history of coronary artery disease, and 16% had diabetes mellitus. The mean (SD) baseline LDL-C by ultracentrifugation was 123 (28) mg/dL. Subjects with a Lp(a) greater than or equal to the median at baseline were more likely to be black and to have a prior history of coronary artery disease and hypertension as well as higher highdensity lipoprotein and lower triglycerides. The median (IQR) Lp(a) values at baseline in patients with and without a history of coronary artery disease were 63 (15-181 nmol/L) and 40 (12-152 nmol/L), respectively (P=0.03). In a multivariable model, race, history of hypertension, history of coronary artery disease, higher baseline high-density lipoprotein, and lower baseline triglycerides were significant independent predictors of Lp(a) greater than or equal to the median at baseline ( Table 2) .
Among patients who had Lp(a) measured at both baseline and week 12 (n=612), all doses of AMG145 significantly reduced Lp(a) from baseline to week 12 compared with placebo (P<0.001 for each AMG145 dose compared with placebo; Figure 1 ). Compared with placebo, the mean percent reduction in Lp(a) from baseline to week 12 was 18.0%, 32.1%, and 32.3% for subjects receiving AMG145 70 mg, 105 mg, and 140 mg, respectively, and 18.2%, 22.8%, and 23.1% for subjects receiving AMG145 280 mg, 350 mg, and 420 mg every 4 weeks, respectively. In sensitivity analyses restricted to patients who had an Lp(a) level above the limit of detection at baseline (n=554), the effect of AMG145 compared with placebo on Lp(a) levels from baseline to week 12 was similar, with reductions of 20% to 36% and reductions of 21% to 26% for subjects receiving AMG145 every 2 and every 4 weeks, respectively (P<0.001 for each AMG145 dose compared with placebo; Figure III in the online-only Data Supplement). Reductions in ultracentrifugation LDL-C and ApoB for each AMG145 dose compared with placebo are shown side by side in Figure 2 . The median (IQR) absolute changes in Lp(a) and achieved Lp(a) levels at week 12 across the different dose regimens are shown in Table 3 .
Among subjects who were allocated to and completed treatment with AMG145 and had an Lp(a) level above the limit of detection at baseline (n=405), there was only a moderate positive correlation between the percent change in Lp(a) and the percent change in LDL-C from baseline to week 12 (ρ=0.33, P<0.001; Figure 3 ). 18 The correlation with the percent change in ApoB was similar (ρ=0.36, P<0.001; Figure IV in the online-only Data Supplement), whereas the correlation with the percent change in PCSK9 was weak (ρ=0.12, P=0.013). The correlations with the percent change in other lipid parameters are shown in Table  II in the online-only Data Supplement. In addition, there was only a moderate correlation between LDL-C achieved at week 12 and percent change in Lp(a) (ρ=0.30, P<0.001). Figure 4 demonstrates the percent reduction in Lp(a) among subjects receiving AMG145 140 mg every 2 weeks or 420 mg every 4 weeks across key subgroups. The percent change in Lp(a) was consistent regardless of age, sex, race, history of diabetes mellitus, intensity of background statin therapy, and LDL-C at study entry for AMG145 140 mg every 2 weeks and 420 mg every 4 weeks. There was a significant treatment interaction for the mean percent change in Lp(a) based on baseline Lp(a). Specifically, there were lesser percent reductions in Lp(a) across progressively higher quartiles of baseline Lp(a) for AMG145 140 mg every 2 weeks and 420 mg every 4 weeks (P int <0.001 for both AMG145 doses versus placebo; Figure 4 ). Conversely, there were greater absolute reductions in Lp(a) from baseline to week 12 across higher quartiles of baseline Lp(a) for AMG145 140 mg every 2 weeks (P int =0.003), with a similar appearance for AMG145 420 mg every 4 weeks (P int =0.32) ( Figure 5 ). In terms of correlations, for baseline Lp(a) and the percent reduction in Lp(a), the correlation coefficient was −0.24 (P<0.001), whereas for baseline Lp(a) and the absolute decrease in Lp(a), the correlation coefficient was 0.49 (P<0.001) ( Figure  VA and VB in the online-only Data Supplement).
Discussion
Several prior studies have suggested that Lp(a) is an important risk factor for the development of CVD. [4] [5] [6] In a meta-analysis of 36 studies including 126 634 individuals, there was a significant, curvilinear association between Lp(a) and the risk of coronary death, nonfatal myocardial infarction, and ischemic stroke. 4 After adjustment for age, sex, systolic blood pressure, smoking status, history of diabetes mellitus, body mass index, and total cholesterol, the risk ratio (95% confidence interval) per 3.5-fold (1-SD) higher Lp(a) level was 1.13 (1.09-1.18) for coronary heart disease and 1.10 (1.02-1.18) for ischemic stroke. Mendelian randomization data from 42 000 subjects in the Copenhagen City Heart Study suggested a significant causal association between elevated Lp(a) levels and the risk of myocardial infarction. 5 Another genetic analysis identified 2 common variants in the LPA gene that were strongly associated with both increased levels of Lp(a) and an increased risk of coronary disease, further supporting a causal role of Lp(a) in coronary disease. 6 Supporting the association between Lp(a) and CAD, in our study we found that a prior history of coronary artery disease was independently associated with higher levels of Lp(a) at baseline.
We found that compared with placebo, AMG145 significantly lowers Lp(a) in subjects with hypercholesterolemia receiving background therapy with statin with or without ezetimibe. In addition, we observed dose-response relationships at both dosing frequencies, with progressively more robust reductions in Lp(a), up to 32%, from baseline to week 12. However, similar to observations for ultracentrifugation LDL-C and ApoB, there appeared to be a plateau effect, which is consistent with the biology of PCSK9 inhibition with AMG145. When our analysis was restricted to subjects with an Lp(a) level above the limit of detection at baseline, AMG145 reduced Lp(a) by up to 36%. Of note, these measurements were made at the end of the AMG145 dosing intervals, and therefore, akin to our observations for LDL-C, 16 they likely underestimate the magnitude of reduction. Importantly, we found that the reduction in Lp(a) with AMG145 was consistent across several important subgroups including age, sex, race, history of diabetes mellitus, and background statin regimen. We found a significant interaction in the percent change in Lp(a) from baseline to week 12 based on baseline Lp(a). There were lesser percent reductions in Lp(a) from baseline to week 12 with progressively higher quartiles of baseline Lp(a). Conversely, there were greater absolute reductions in Lp(a) from baseline to week 12 with progressively higher quartiles of baseline Lp(a). These observations likely reflect, at the lower end of the baseline Lp(a) distribution, the mathematical inability to effect large absolute reductions, and, at the higher end of the markedly positively skewed baseline Lp(a) distribution, subjects who enjoyed larger absolute but comparatively smaller percent reductions in Lp(a).
The precise mechanism by which AMG145 lowers Lp(a) is unknown and warrants further research but is presumed to be a consequence of either decreased production or increased clearance. Given the close homology between Lp(a) and LDL-C and the dramatic reductions in LDL-C with AMG145, it is possible that Lp(a) could be cleared via the LDL receptor or the verylow-density lipoprotein receptor. Interestingly, patients with homozygous familial hypercholesterolemia have higher levels of Lp(a) than relatives with similar Lp(a) isoforms. 19 However, cell culture and animal studies have yielded mixed results, with some supporting and others casting doubt on the potential relevance of the LDL receptor for clearance of Lp(a). [20] [21] [22] [23] [24] [25] Moreover, it remains unknown whether increased clearance of Lp(a) via the LDL receptor might be triggered in the setting of very low circulating levels of LDL-C, as existed for our patients. Alternatively, lower levels of LDL-C and hence ApoB may limit substrate availability for the synthesis of Lp(a). We found only a moderate correlation between the percent change in Lp(a) and both the percent change in and achieved levels of LDL-C, but because AMG145 reduced both LDL-C and Lp(a) in a dose-dependent manner, it is not possible to disentangle the 2 effects. Finally, whatever the exact mechanism of Lp(a) reduction, this appears to be a class effect of PCSK9 inhibitors rather than a unique property of AMG145 because similar reductions were observed with the monoclonal antibody SAR236553/REGN727. 26 In terms of other options to lower Lp(a), treatment with niacin lowers levels, but large clinical trials of niacin in patients with dyslipidemia [not specifically selected for Lp(a) levels] have failed to show any clinical benefit. 27, 28 Other therapies offer modest reductions in Lp(a), [11] [12] [13] and statins appear, if anything, to increase Lp(a). 14, 15 Trials of varying size are now ongoing with novel therapies that, in addition to other lipidmodifying effects, also reduce Lp(a), such as the cholesteryl ester transfer protein inhibitor anacetrapib 29 and mipomersen. 30 A specific antisense oligonucleotide targeted to Apo(a) has been shown to substantially lower Lp(a) in animal models. 31 Several analytical points in regard to our study are worth noting. First, the distribution of Lp(a) was heavily positively skewed at baseline, similar to observations in other epidemiological studies. For that reason, we reported median (IQR) values and used nonparametric tests for statistical inference. Second, our findings are similar to those of other epidemiological studies that demonstrated heterogeneity of baseline Lp(a) by race. This observation has important implications for comparisons across studies drawing from different populations. Third, our assay had a limit of detection of 5 nmol/L such that 58 subjects (9%) had Lp(a) levels at or below the limit of detection at baseline. However, we used an immunoturbidometric assay that is independent of Apo(a) isoform and is preferred over alternative assays that rely on a measurement of the entire mass of Lp(a) and are more vulnerable to bias. 14 In addition, we performed sensitivity analyses excluding patients with Lp(a) levels below the limit of detection. Although we did not detect statistically significant interactions between baseline clinical characteristics and the effect of AMG145 on Lp(a) levels, this study was not powered to do so, and confirmation from data being gathered in larger ongoing trials will be important. Finally, our estimates of the change in Lp(a) are based on measurements at week 12, which is at the end of the dosing interval, and likely underestimate the true biological effect. Furthermore, the kinetics of Lp(a) reduction may differ from those observed for LDL-C, and further analyses of samples during the dosing interval may offer additional insights to both the timing and extent of Lp(a) reduction with AMG145.
In conclusion, the reduction in Lp(a) with AMG145, a monoclonal antibody to PCSK9, offers an additional, complementary benefit beyond robust LDL-C reductions with regard to a patient's atherogenic lipid profile. Although the clinical benefit of Lp(a) reduction remains undefined, these data lend further support to studying the impact of PCSK9 inhibition with AMG145 in a phase 3 clinical outcomes trial.
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